| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Invitation to participate |
| Process | Cost Comparison Standard |
| ID number | 6411 |
Provisional Schedule
| Expected publication | 02 July 2025 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email Team5@nice.org.uk
| External Assessment Group | Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Stakeholders
| Companies sponsors | AstraZeneca (dapagliflozin) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Kidney Research UK |
| Professional groups | Royal College of Physicians |
| UK Kidney Association | |
| Comparator companies | Boehringer Ingelheim (empagliflozin) |
| General commentators | All Wales Therapeutic and Toxicology Centre |
| British National Formulary | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare Products Regulatory Agency | |
| NHS Wales Joint Commissioning Committee | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Relevant research groups | National Institute for Health & Care Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 May 2025 - 13 June 2025 | Final draft guidance |
| 17 May 2024 | Invitation to participate |
| 17 May 2024 | Invitation to participate |
| 17 May 2024 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual